vestimИзвестия Национальной академии наук Беларуси. Серия медицинских наукProceedings of the National Academy of Sciences of Belarus, Medical series1814-60232524-2350The Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1814-6023-2020-17-3-275-286vestim-688Research ArticleКЛИНИЧЕСКАЯ И ЭКСПЕРИМЕНТАЛЬНАЯ МЕДИЦИНАCLINICAL AND EXPERIMENTAL MEDICINEОценка качества жизни пациентов после радикального лечения рака предстательной железыQuality of life evaluation of patients after radical treatment of prostate cancerhttps://orcid.org/0000-0002-3066-3185ГолдыцкийС. О.GoldytskiS. O.

Голдыцкий Сергей Олегович ‒ старший преподаватель

пр. Фрунзе, 27, 21009, г. Витебск

Sergei O. Goldytski ‒ Senior Lecturer

27, Frunze Ave., 210019? Vitebsk

gsomd2011@gmail.comhttps://orcid.org/0000-0002-1324-3656ДемешкоП. Д.DemeshkoP. D.

Демешко Павел Дмитриевич – доктор медицинских наук, заведующий отделом

223040, агр. Лесной, Минский р-н

Pavel D. Demeshko ‒ D. Sc. (Med.), Head of the Department

223040, Lesnoy, Minsk region

pdemeshko@icloud.comКрасныйС. А.KrasnyS. A.

Красный Сергей Анатольевич – член-корреспондент, доктор медицинских наук, профессор, заместитель директора

223040, агр. Лесной, Минский р-н

Sergeу A. Krasny – Corresponding Member, D. Sc. (Med.), Professor, Deputy Director

223040, Lesnoy, Minsk region

sergeykrasny@tut.byВитебский государственный медицинский университетVitebsk State Medical UniversityРеспубликанский научно-практический центр онкологии и медицинской радиологии им. Н. Н. АлександроваN. N. Alexandrov National Cancer Centre of Belarus202029082020173275286Copyright © Голдыцкий С.О., Демешко П.Д., Красный С.А., 20202020Голдыцкий С.О., Демешко П.Д., Красный С.А.Goldytski S.O., Demeshko P.D., Krasny S.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestimed.belnauka.by/jour/article/view/688

В статье представлен обзор современных данных о качестве жизни онкологических пациентов после проведенного радикального лечения рака предстательной железы, а также о функциональных результатах этого лечения. Основная цель работы ‒ оценка функциональных результатов у пациентов после радикальной простатэктомии, сочетанной лучевой терапии и брахитерапии высокой мощностью дозы в монорежиме спустя 8–12 мес. после проведенного лечения. В исследование было включено 148 пациентов, проходивших лечение с 2017 по 2018 г. Функциональные результаты и качество жизни пациентов оценивали посредством специализированного опросника. Полученные после проведения лучевой терапии результаты свидетельствуют о лучших функциональных результатах и более высоком уровне качества жизни пациентов, чем после выполнения радикальной простатэктомии.

The article provides an overview of the current data on the quality of life in cancer patients, as well as the functional results of radical treatment of prostate cancer. The main goal was to evaluate the functional results in patients after radical prostatectomy, combined radiation therapy, and high dose-rate brachytherapy in 8 to 12 months after treatment. The study included 148 patients treated from 2017 to 2018. The life quality was assessed by specialized questionnaire. The obtained results indicate the better functional results and a higher level of the quality of life of patients after radiation therapy, compared with radical prostatectomy.

рак предстательной железырадикальная простатэктомиясочетанная лучевая терапиябрахитерапияфункциональные результатыкачество жизниопросникprostate cancerradical prostatectomycombined radiotherapybrachytherapyfunctional resultsquality of lifequestionnaireReferencesThe development of the WHO quality of life assessment instruments (the WHOQOL) / WHOQOL Group // Quality of life assessment: international perspectives : proceedings of the joint-meeting organized by the World Health Organization and the Fondation IPSEN in Paris, July 2–3, 1993 / ed. : J. Orley, W. Kuyken. – Berlin, 1994. – P. 41−57.WHOQOL Group. The development of the WHO quality of life assessment instruments (the WHOQOL). Quality of life assessment: international perspectives: proceedings of the joint-meeting organized by the World Health Organization and the Fondation IPSEN in Paris, July 2–3, 1993. Berlin, 1994, pp. 41–57.Базисные принципы и методология доказательной медицины / В. И. Петров // Вестн. Волгоград. гос. мед. ун-та. – 2011. – № 2. – С. 3–9.Petrov V. I. Basic principles and methodology of evidence-based medicine. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta [Bulletin of Volgograd State Medical University], 2011, no. 2, pp. 3–9 (in Russian).Hays, R. D. Measurement and modeling of health-related quality of life / R. D. Hays, B. B. Reeve // International Encyclopedia of public health / ed. : K. Heggenhougen, S. R. Quah. Amsterdam ; Boston, 2008. – P. 241–252.Hays R. D., Reeve B. B. Measurement and modeling of health-related quality of life. International Encyclopedia of public health. Amsterdam, Boston, 2008, pp. 241–252.Torrance, G. W. Utility approach to measuring health-related quality of life / G. W. Torrance // J. Chron. Dis. – 1987. – Vol. 40, N 6. – P. 593–600. https://doi.org/10.1016/0021-9681(87)90019-1Torrance G. W. Utility approach to measuring health-related quality of life. Journal of Chronic Disease, 1987, vol. 40, no. 6, pp. 593–600. https://doi.org/10.1016/0021-9681(87)90019-1Ebrahim, S. Clinical and public health perspectives and applications of health-related quality of life measurement / S. Ebrahim // Soc. Sci. Med. – 1995. – Vol. 41, N 10. – P. 1383–1394. https://doi.org/10.1016/0277-9536(95)00116-OEbrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Social Science Medicine, 1995, vol. 41, no. 10, pp. 1383–1394. https://doi.org/10.1016/0277-9536(95)00116-OThe role and cost-effectiveness analysis in health and medicine / L. B. Russel [et al.] // JAMA. – 1996. – Vol. 276, N 14. – P. 1172–1177. https://doi.org/10.1001/jama.1996.03540140060028Russel L. B., Gold M. R., Siegel J. E., Daniels N., Weinstein M. C. The role and cost-effectiveness analysis in health and medicine. JAMA: The Journal of the American Medical Association, 1996, vol. 276, no. 14, pp. 1172–1177. https://doi.org/10.1001/jama.1996.03540140060028Outcomes of cancer treatment for technology assessment and cancer treatment guidelines / American Society of Clinical Oncology // J. Clin. Oncol. – 1996. – Vol. 14, N 2. – P. 671–679. https://doi.org/10.1200/JCO.1996.14.2.671American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. Journal of Clinical Oncology, 1996, vol. 14, no. 2, pp. 671–679. https://doi.org/10.1200/JCO.1996.14.2.671Health-related quality of life assessment and reported outcomes in leukaemia randomized controlled trials: a systematic review to evaluate the added value in supporting clinical decision-making / F. Efficace [et al.] // Eur. J. Cancer. – 2008. – Vol. 44, N 11. – P. 1497–1506. https://doi.org/10.1016/j.ejca.2008.03.017Efficace F., Kemmler G., Vignetti M., Mandelli F., Molica S., Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomized controlled trials: a systematic review to evaluate the added value in supporting clinical decisionmaking. European Journal of Cancer, 2008, vol. 44, no. 11, pp. 1497–1506. https://doi.org/10.1016/j.ejca.2008.03.017Cancer incidence and mortality projections in the UK until 2035 / C. R. Smittenaar [et al.] // Br. J. Cancer. – 2016. – Vol. 115, N 9. – P. 1147–1155. https://doi.org/10.1038/bjc.2016.304Smittenaar C. R., Petersen K. A., Stewart K., Moitt N. Cancer incidence and mortality projections in the UK until 2035. British Journal of Cancer, 2016, vol. 115, no. 9, pp. 1147–1155. https://doi.org/10.1038/bjc.2016.304High levels of untreated distress and fatigue in cancer patients / L. E. Carlson [et al.] // Br. J. Cancer. – 2004. – Vol. 90, N 12. – P. 2297–2304. https://doi.org/10.1038/sj.bjc.6601887Carlson L. E., Angen M., Cullum J., Goodey E., Koopmans J., Lamont L. [et al.]. High levels of untreated distress and fatigue in cancer patients. British Journal of Cancer, 2004, vol. 90, no. 12, pp. 2297–2304. https://doi.org/10.1038/sj.bjc.6601887Are fatigue, depression and anxiety associated with labour market participation among patients diagnosed with haematological malignancies? A prospective study / T. A. Horsboel [et al.] // Psycho-Oncology. – 2015. – Vol. 24, N 4. – P. 408–415. https://doi.org/10.1002/pon.3658Horsboel T. A., Bültmann U., Nielsen C. V., Nielsen B., Andersen N. T., de Thurah A. Are fatigue, depression and anxiety associated with labour market participation among patients diagnosed with haematological malignancies? A prospective study. Psycho-Oncology, 2015, vol. 24, no. 4, pp. 408–415. https://doi.org/10.1002/pon.3658Toward a national initiative in cancer rehabilitation: recommendations from subject matter expert group / N. L. Stout [et al.] // Arch. Phys. Med. Rehabil. – 2016. – Vol. 97, N 11. – P. 2006–2015. https://doi.org/10.1016/j.apmr.2016.05.002Stout N. L., Silver J. K., Silver J. K., Raj V. S., Rowland Ju., Gerber L., Cheville A. [et al]. Toward a national initiative in cancer rehabilitation: recommendations from subject matter expert group. Archives of Physical Medicine and Rehabilitation, 2016, vol. 97, no. 11, pp. 2006–2015. https://doi.org/10.1016/j.apmr.2016.05.002Attitudes of urologists towards HRQOL and its clinical use / A. Schmick [et al.] // BMC Urol. – 2017. – Vol. 17. – Art. 46. https://doi.org/10.1186/s12894-017-0235-1Schmick A., Juergensen M., Rohde V., Katalinic A., Waldmann A. Attitudes of urologists towards HRQOL and its clinical use. BMC Urology, 2017, vol. 17, art. 46. https://doi.org/10.1186/s12894-017-0235-1Blazeby, J. M. The prognostic value of quality of life scores during treatment for esophageal cancer / J. M. Blazeby, S. T. Brookes, D. Aldersona // Gut. – 2001. – Vol. 49, N 2. – P. 227–230. http://dx.doi.org/10.1136/gut.49.2.227Blazeby J. M., Brookes S.T., Aldersona D. The prognostic value of quality of life scores during treatment for esophageal cancer. Gut, 2001, vol. 49, no. 2, pp. 227–230. http://dx.doi.org/10.1136/gut.49.2.227EORTC clinical groups: baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials / C. Quinten [et al.] // Lancet. Oncol. – 2009. – Vol. 10, N 9. – P. 865–871. https://doi.org/10.1016/S1470-2045(09)70200-1Quinten C., Coens C., Mauer M., Comte S., Sprangers M., Cleeland Ch., Osoba D., Bjordal K., Bottomley A. EORTC clinical groups: baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncology, 2009, vol. 10, no. 9, pp. 865–871. https://doi.org/10.1016/S1470-2045(09)70200-1The prognostic significance of patient-reported outcomes in cancer clinical trials / C. C. Gotay [et al.] // J. Clin. Oncol. – 2008. – Vol. 26, N 8. – P. 1355–1363. https://doi.org/10.1200/JCO.2007.13.3439Gotay C. C., Kawamoto C. T., Bottomley A., Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of Clinical Oncology, 2008, vol. 26, no. 8, pp. 1355–1363. https://doi.org/10.1200/JCO.2007.13.3439Jylhä, M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model / M. Jylhä // Soc. Sci. Med. – 2009. – Vol. 69, N 3. – P. 307–316. https://doi.org/10.1016/j.socscimed.2009.05.013Jylhä M. What is self-rated health and why does it predict mortality? Towards a unified conceptual model. Social Science Medicine, 2009, vol. 69, no. 3, pp. 307–316. https://doi.org/10.1016/j.socscimed.2009.05.013Guideline for good clinical practice. ICN harmonized tripartite guideline. – Geneva : WHO, 1996. – 56 p.Guideline for Good Clinical Practice. ICN Harmonized Tripartite Guideline. Geneva, World Health Organization, 1996. 56 p.Quality-of-life measurement in advanced cancer: assessing the individual / D. Waldron [et al.] // J. Clin. Oncol. – 1999. – Vol. 17, N 11. – P. 3603–3611. https://doi.org/10.1200/JCO.1999.17.11.3603Waldron D., O’Boyle C. A., Kearney M., Moriarty M., Carney D. Quality-of-life measurement in advanced cancer: assessing the individual. Journal Clinical Oncology, 1999, vol. 17, no. 11, pp. 3603–3611. https://doi.org/10.1200/JCO.1999.17.11.3603The use, feasibility and psychometric properties of an individualized quality-of-life instrument: a systematic review of the SEIQoL-DW / L. Wettergren [et al.] // Qual. Life. Res. – 2009. – Vol. 18, N 6. – P. 737–746. https://doi.org/10.1007/s11136-009-9490-2Wettergren L., Kettis-Lindblad Å., Sprangers M., Ring L. The use, feasibility and psychometric properties of an individualized quality-of-life instrument: a systematic review of the SEIQoL-DW. Quality of Life Research, 2009, vol. 18, no. 6, pp. 737–746. https://doi.org/10.1007/s11136-009-9490-2Anderson, R. T. Critical review of the international assessments of health-related quality of life / R. T. Anderson, N. K. Aaronson, D. Wilkin // Qual. Life. Res. – 1993. – Vol. 2, N 6. – P. 369–395. https://doi.org/10.1007/BF00422215Anderson R. T., Aaronson N. K., Wilkin D. Critical review of the international assessments of health-related quality of life. Quality of Life Research, 1993, vol. 2, no. 6, pp. 36, 9–395. https://doi.org/10.1007/BF00422215Australian WHOQoL instruments: user’s manual and interpretation guide / B. Murphy [et al.]. – Melbourne, Australian WHOQoL Field Study Centre, 2000.Murphy B., Herrman H. Hawthorne G., Pinzone T., Evert H., Herrman H. Australian WHOQoL instruments: User’s manual and interpretation guide. Melbourne, Australian WHOQoL Field Study Centre, 2000.The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines / R. Etzioni [et al.] // Cancer. – 2012. – Vol. 118, N 23. – P. 5955–5963. https://doi.org/10.1002/cncr.27594Etzioni R., Gulati R., Tsodikov A., Wever E. M., Penson D. F., Heijnsdijk E. A. M. [et al.]. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer, 2012, vol. 118, no. 23, pp. 5955–5963. https://doi.org/10.1002/cncr.27594Prostate cancer mortality in areas with high and low prostate cancer incidence / P. Stattin [et al.] // J. Nat. Cancer Inst. – 2014. – Vol. 106, N 3. – P. dju007. https://doi.org/10.1093/jnci/dju007Stattin P., Carlsson S., Vickers A., Hugosson J., Lilja H., Jonsson H. Prostate cancer mortality in areas with high and low prostate cancer incidence. Journal of the National Cancer Institute, 2014, vol. 106, no. 3, p. dju007. https://doi.org/10.1093/jnci/dju007Скрининг рака предстательной железы в Республике Беларусь / С. А. Красный [и др.]. – Минск : Принтхаус, 2015. – 158 с.Krasnyi S. A., Sukonko O. G., Tarend’ D. T., Moiseev P. I., Polyakov S. L. Prostate cancer screening in the Republic of Belarus. Minsk, Printkhaus Publ., 2015. 158 p. (in Russian).Статистика онкологических заболеваний в Республике Беларусь 2007–2016: Белорусский канцер-регистр / А. Е. Океанов [и др.] ; под ред. О. Г. Суконко. – Минск : РНПЦ ОМР им. Н. Н. Александрова, 2017. – 286 c.Okeanov A. E., Moiseev P. I., Levin L. F., Evmenenko A. A., Sukonko O. G. Statistics of oncological diseases in the Republic of Belarus 2007–2016: Belarusian Cancer Register. Minsk, Belarusian Republican Scientific and Practical Center of Oncology and Medical Radiology named after N. N. Alexandrov, 2017. 286 p. (in Russian).Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis / J. Hayes [et al.] // Ann. Int. Med. – 2013. – Vol. 158, N 12. – P. 853–860. https://doi.org/10.7326/0003-4819-158-12-201306180-00002Hayes J., Ollendorf D., Pearson S., Barry M. J., Kantoff Ph. W., Lee P. A., McMahon P. M. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Annals of Internal Medicine, 2013, vol. 158, no. 12, pp. 853–860. https://doi.org/10.7326/0003-4819-158-12-201306180-00002Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer / A. Kalbasi [et al.] // JAMA Oncol. – 2015. – Vol. 1, N 7. – P. 897–906. https://doi.org/10.1001/jamaoncol.2015.2316Kalbasi A., Li J., Berman A., Swisher-McClure S., Smaldone M., Uzzo R. G., Small D. S., Mitra N., Bekelman J. E. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncology, 2015, vol. 1, no. 7, pp. 897–906. https://doi.org/10.1001/jamaoncol.2015.2316High-dose-rate monotherapy for localized prostate cancer: 10-year results / H. Hauswald [et al.] // Int. J. Radiat. Oncol. Biol. Phys. – 2016. – Vol. 94, N 4. – P. 667–674. https://doi.org/10.1016/j.ijrobp.2015.07.2290Hauswald H., Kamrava M., Fallon J., Wang P.-Ch., Park S.-Ju., Van T., Borja L., Steinberg M. L., Demanes D. J. High-dose-rate monotherapy for localized prostate cancer: 10-year results. International Journal of Radiation Oncology, 2016, vol. 94, no. 4, pp. 667–674. https://doi.org/10.1016/j.ijrobp.2015.07.2290Prospective quality of life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy / C. Jeldres [et al.] // Cancer. – 2015. – Vol. 121, N 14. – P. 2465–2473. https://doi.org/10.1002/cncr.29370Jeldres C., Cullen J., Hurwitz L., Wolff E. M., Levie K. E., Odem-Davis K. [et al.]. Prospective quality of life outcomes for low-risk prostate cancer: active surveillance versus radical prostatectomy. Cancer, 2015, vol. 121, no. 14, pp. 2465–2473. https://doi.org/10.1002/cncr.29370Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study / J. Fridriksson [et al.] // Scand. J. Urol. – 2016. – Vol. 50, N 5. – P. 338–345. https://doi.org/10.1080/21681805.2016.1194460Fridriksson J., Folkvaljon Y., Nilsson P., Robinson D., Franck-Lissbrant I., Ehdaie B., Eastham J. A., Widmark A., Karlsson C. T., Stattin P. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scandinavian Journal of Urology, 2016, vol. 50, no. 5, pp. 338–345. https://doi.org/10.1080/21681805.2016.1194460Population-based study of long-term functional outcomes after prostate cancer treatment / S. Carlsson [et al.] // BJU Int. – 2016. – Vol. 117, N 6B. – P. E36–E45. https://doi.org/10.1111/bju.13179Carlsson S., Drevin L., Loeb S., Widmark A., Lissbrant I. F., Robinson D., Johansson E., Stattin P., Fransson P. Population-based study of long-term functional outcomes after prostate cancer treatment. BJU International, 2016, vol. 117, no. 6B, pp. E36–E45. https://doi.org/10.1111/bju.13179Long-term quality-of-life outcomes after radical prostatectomy of watchful waiting: the Scandinavian Prostate Cancer Group-4 randomized trial / E. Johansson [et al.] // Lancet Oncol. – 2011. – Vol. 12, N 9. – P. 891–899. https://doi.org/10.1016/S1470-2045(11)70162-0Johansson E., Steineck G., Holmberg L., Johansson J.-E., Nyberg T., Ruutu M., Bill-Axelson A. Long-term qualityof-life outcomes after radical prostatectomy of watchful waiting: the Scandinavian Prostate Cancer Group-4 randomized trial. Lancet Oncology, 2011, vol. 12, no. 9, pp. 891–899. https://doi.org/10.1016/S1470-2045(11)70162-0Quality of life and satisfaction with outcome among prostate-cancer survivors / M. Sanda [et al.] // N. Engl. J. Med. – 2008. – Vol. 358. – P. 1250–1261. https://doi.org/10.1056/NEJMoa074311Sanda M., Dunn R., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. New England Journal of Medicine, 2008, vol. 358, pp. 1250–1261. https://doi.org/10.1056/NEJMoa074311Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer / J. Donnovan [et al.] // N. Engl. J. Med. – 2016. – Vol. 375, N 15. – P. 1425–1437. https://doi.org/10.1056/NEJMoa1606221Donnovan J., Hamdy F., Lane M., Mason M., Metcalfe Ch., Walsh E. [et al.]. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 2016, vol. 375, no. 15, pp. 1425–1437. https://doi.org/10.1056/NEJMoa1606221Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques / M. Morgan [et al.] // J. Contemp. Brachytherapy. – 2018. – Vol. 10, N 6. – P. 495–502. https://doi.org/10.5114/jcb.2018.81024Morgan M., Press R., Cutrell P., Zhang Ch., Chen Zh., Rahnema S. [et al.]. Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. Journal of Contemporary Brachytherapy, 2018, vol. 10, no. 6, pp. 495–502. https://doi.org/10.5114/jcb.2018.81024Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire / M. Leeuwen [et al.] // Health Qual. Life Outcomes. – 2018. – Vol. 16, N 1. – P. 114. https://doi.org/10.1186/s12955-018-0920-0Leeuwen M., Husson O., Alberti P., Arraras J. I., Chinot O. L., Costantini A. [et al.] Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health and Quality of life outcomes, 2018, vol. 16, no. 114. https://doi.org/10.1186/s12955-018-0920-0The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology / N. Aaronson [et al.] // J. Nat. Cancer Inst. – 1993. – Vol. 85, N 5. – P. 365–376. https://doi.org/10.1093/jnci/85.5.365Aaronson N., Ahmedzai S., Bergmann B., Bullinger M., Cull A., Duez N. J. [ et al.]. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 1993, vol. 85, no. 5, pp. 365–376. https://doi.org/10.1093/jnci/85.5.365Pearce, N. J. Measuring quality of life in cancer survivors: a methodological review of existing scales / N. J. Pearce, R. Sanson-Fisher, H. Campbell // Psycho-Oncology. – 2007. – Vol. 17, N 7. – P. 629–640. https://doi.org/10.1002/pon.1281Pearce N. J., Sanson-Fisher R., Campbell H. Measuring quality of life in cancer survivors: a methodological review of existing scales. Psycho-Oncology, 2007, vol. 17, no. 7, pp. 629–640. https://doi.org/10.1002/pon.1281Baker, F. Development of the Satisfaction with Life Domains Scale for Cancer / F. Baker, B. Curbow, J. R. Wingard // J. Psychosoc. Oncol. – 2008. – Vol. 10, N 3. – P. 75–90. https://doi.org/10.1300/j077v10n03_05Baker F., Curbow B., Wingard J. R. Development of the satisfaction with life domains scale for cancer. Journal of Psychosocial Oncology, 2008, vol. 10, no. 3, pp. 75–90. https://doi.org/10.1300/j077v10n03_05Avis, N. E. Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for long-term cancer survivors in a sample of breast cancer survivors / N. E. Avis, E. Ip, K. L. Foley // Health Qual. Life Outcomes. – 2006. – Vol. 4. – Art. 92. https://doi.org/10.1186/1477-7525-4-92Avis N. E., Ip E., Foley K. L. Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for longterm cancer survivors in a sample of breast cancer survivors. Health and Quality of Life Outcomes, 2006, vol. 4, art. 92. https://doi.org/10.1186/1477-7525-4-92The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure / M. Litwim [et al.] // Med. Care. – 1998. – Vol. 36, N 7. – P. 1002–1012. https://doi.org/10.1097/00005650-199807000-00007Litwim M., Hays R., Fink A., Ganz P. A., Leake B., Brook R. H. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Medical Care, 1998, vol. 36, no. 7, pp. 1002–1012. https://doi.org/10.1097/00005650-199807000-00007Measuring and predicting prostate cancer related quality of life changes using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) / J. Chipman [et al.] // J. Urol. – 2014. – Vol. 191, N 3. – P. 638–645. https://doi.org/10.1016/j.juro.2013.09.040Chipman J., Sanda M., Dune R., Wei J. T., Litwin M. S., Crociani C. M., Regan M. M., Chang P. Measuring and predicting prostate cancer related quality of life changes using the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP). Journal of Urology, 2014, vol. 191, no. 3, pp. 638–645. https://doi.org/10.1016/j.juro.2013.09.040Апробация «Универсального опросника качества жизни больных раком предстательной железы» / С. А. Ракул [и др.] // Онкоурология. – 2009. – Т. 5, № 2. – С. 64–73.Rakul S. A., Petrov S. B., Ivanova M. D., Petrova N. N. Testing of the “Universal Questionnaire for the Quality of Life of Patients with Prostate Cancer”. Onkourologiya [Oncourology], 2009, vol. 5, no. 2, pp. 64–73 (in Russian).Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomized controlled study / G. D. Coughlin [et al.] // Lancet Oncol. – 2018. – Vol. 19, N 8. – P. 1051–1060. https://doi.org/10.1016/S1470-2045(18)30357-7Coughlin G. D., Yaxley J. W., Chambers S. K., Occhipinti S., Samaratunga H., Zajdlewicz L. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomized controlled study. Lancet Oncology, 2018, vol. 19, no. 8, pp. 1051–1060. https://doi.org/10.1016/S1470-2045(18)30357-7Брахитерапия высокой мощностью дозы при раке предстательной железы / С. О. Голдыцкий [и др.] // Здравоохранение. – 2019. – № 3. – С. 40–45.Goldytskii S. O., Demeshko P. D., Krasnyi S. A., Suslova V. A. High-dose brachytherapy for prostate cancer. Zdravookhranenie = Healthcare, 2019, no. 3, pp. 40–45 (in Russian).

The authors declare that there are no conflicts of interest present.